Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first ...

Adaptimmune Therapeutics is prepping for another FDA submission after 42% of patients with sarcoma responded to the company's ...

MRCLS had clinical responses with lete-celResults include six complete responses (6/64); twenty-one partial responses ...

Adaptimmune Therapeutics ADAP is preparing to release its quarterly earnings on Wednesday, 2024-11-13. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...

European equities traded in the US as American depositary receipts were higher Thursday, rising 1.11% to 1,352.23 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on HCA Healthcare (HCA – Research Report), ...

Philadelphia, Pennsylvania and Oxford, United Kingdom-- (Newsfile Corp. - November 5, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor ...

The stock of Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) has decreased by -3.61 when compared to last closing price of 0.70. Despite this, the company has experienced a -13.48% fall in its stock ...